Molnupiravir lowers long COVID risk: study

Antiviral still has a role to play despite guidelines advising against routine use for mild disease, says Associate Professor Paul Griffin.
Rachel Fieldhouse
Associate Professor Paul Griffin
Associate Professor Paul Griffin.

Molnupiravir may cut the risk of long COVID symptoms as well as post-acute death, regardless of a patient’s vaccination status or prior infection, US epidemiologists report. 

Their study of nearly 230,000 veterans with COVID-19 suggests the antiviral is associated with a 14% lower relative risk of post-acute sequalae versus no treatment.